Erik Johan Frostegård
Directeur/Membre du Conseil chez ANNEXIN PHARMACEUTICALS AB
Postes actifs de Erik Johan Frostegård
Sociétés | Poste | Début | Fin |
---|---|---|---|
ANNEXIN PHARMACEUTICALS AB | Directeur/Membre du Conseil | 01/01/2016 | - |
Karolinska Institutet | Corporate Officer/Principal | - | - |
Karolinska University Hospital
Karolinska University Hospital Hospital/Nursing ManagementHealth Services Karolinska University Hospital is a premier health facility and one of Europe's largest teaching hospitals located in Stockholm, Sweden. The Swedish company provides healthcare services for a wide range of disorders, from major public health diseases to rare medical conditions. As a designated provider of highly specialized medical services, they have a primary responsibility for the clinical components of research and education. Together with the world-respected Karolinska Institutet, they lead in medical breakthroughs. The company educates and train tomorrow's medical specialists and healthcare professionals as a major teaching hospital. | Corporate Officer/Principal | - | - |
Historique de carrière de Erik Johan Frostegård
Anciens postes connus de Erik Johan Frostegård
Sociétés | Poste | Début | Fin |
---|---|---|---|
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Directeur/Membre du Conseil | 01/01/2002 | - |
Fondateur | 01/01/2002 | - |
Statistiques
Internationale
Suède | 5 |
Opérationnelle
Director/Board Member | 2 |
Corporate Officer/Principal | 2 |
Founder | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 2 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ANNEXIN PHARMACEUTICALS AB | Health Technology |
Entreprise privées | 2 |
---|---|
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Health Technology |
Karolinska University Hospital
Karolinska University Hospital Hospital/Nursing ManagementHealth Services Karolinska University Hospital is a premier health facility and one of Europe's largest teaching hospitals located in Stockholm, Sweden. The Swedish company provides healthcare services for a wide range of disorders, from major public health diseases to rare medical conditions. As a designated provider of highly specialized medical services, they have a primary responsibility for the clinical components of research and education. Together with the world-respected Karolinska Institutet, they lead in medical breakthroughs. The company educates and train tomorrow's medical specialists and healthcare professionals as a major teaching hospital. | Health Services |
- Bourse
- Insiders
- Erik Johan Frostegård
- Expérience